Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 10, 2015 08:00 ET | Source: MediciNova, Inc.

MediciNova Announces FDA Approval of Protocol for Phase 2 Trial of MN-001 in IPF

LA JOLLA, Calif., Feb. 10, 2015 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (Nasdaq:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange...
February 03, 2015 18:00 ET | Source: MediciNova, Inc.

MediciNova Receives Notice of Allowance for New Patent Covering MN-001 and MN-002 for the Treatment of NASH

LA JOLLA, Calif., Feb. 3, 2015 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (Nasdaq:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange...
February 02, 2015 18:00 ET | Source: MediciNova, Inc.

MN-166 (ibudilast) ALS Abstract Accepted for Dual Presentation at the American Academy of Neurology (AAN) 67th Annual Meeting in Washington, DC

LA JOLLA, Calif., Feb. 2, 2015 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (Nasdaq:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange...
February 01, 2015 18:00 ET | Source: MediciNova, Inc.

MN-166 (ibudilast) Progressive MS Abstract Accepted for Presentation at the American Academy of Neurology (AAN) 67th Annual Meeting in Washington, DC

LA JOLLA, Calif., Feb. 1, 2015 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (Nasdaq:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange...
January 29, 2015 18:00 ET | Source: MediciNova, Inc.

MediciNova Receives New Patent Covering MN-029 (denibulin) di-hydrochloride in Japan

LA JOLLA, Calif., Jan. 29, 2015 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (Nasdaq:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange...
January 28, 2015 08:00 ET | Source: MediciNova, Inc.

MediciNova Announces an Open Investigational New Drug (IND) Application for MN-001 in NASH

LA JOLLA, Calif., Jan. 28, 2015 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (Nasdaq:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange...
December 09, 2014 18:00 ET | Source: MediciNova, Inc.

MediciNova Receives Notice of Allowance for New Patent Covering MN-001 and MN-002 for the Treatment of Liver Disorders

LA JOLLA, Calif., Dec. 9, 2014 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (Nasdaq:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange...
October 23, 2014 19:00 ET | Source: MediciNova, Inc.

U.S. Centers for Disease Control and Prevention (CDC) Supports Recruitment for MediciNova's Clinical Trial of MN-166 (Ibudilast) in ALS

LA JOLLA, Calif., Oct. 23, 2014 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (Nasdaq:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange...
October 22, 2014 19:00 ET | Source: MediciNova, Inc.

MediciNova Announces FDA Granted Orphan Drug Designation to MN-001 (tipelukast) for Idiopathic Pulmonary Fibrosis (IPF)

LA JOLLA, Calif., Oct. 22, 2014 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (Nasdaq:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange...
October 08, 2014 19:00 ET | Source: MediciNova, Inc.

MediciNova Receives Feedback From FDA Regarding Study Protocol for Phase 2 Trial of MN-001 (tipelukast) in NASH

LA JOLLA, Calif., Oct. 8, 2014 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (Nasdaq:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange...